Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 72Neoplasms 64Prostatic Neoplasms 45Colorectal Neoplasms 42Lung Neoplasms 38Carcinoma, Non-Small-Cell Lung 26Pancreatic Neoplasms 21Neoplasm Metastasis 20Hematologic Neoplasms 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 15Ovarian Neoplasms 14Multiple Myeloma 11Motor Activity 11Leukemia, Myeloid, Acute 11Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Glioblastoma 9Colonic Neoplasms 9Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Gastrointestinal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8Rectal Neoplasms 7Melanoma 7

Interventions

Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Progressive Metastatic Castrate Resistant Prostate Cancer × Standard of Care × Clear all
NCT07206056 2026-06-03

TulmiSTAR-01

Novartis

Phase 1/2 Recruiting
188 enrolled
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡